Alexion Pharmaceuticals Inc. in Cheshire said Friday its blood disorder treatment had received regulatory approval in Japan, The Associated Press reports.
Soliris, approved by Japan’s Ministry of Health, Labour and Welfare, treats a rare chronic disease called paroxysmal nocturnal hemoglobinuria, which causes a breakdown of red blood cells and leads to anemia.
It expects to begin commercial sales in Japan by year end.
The drug is already approved in the U.S., Canada, Australia and Europe.
